Cancer du Col de l’Utérus

Objectives

The guideline provides an evidence-informed national framework for preventing, detecting, diagnosing, treating and following up cervical cancer in Morocco, while supporting clinical decision-making rather than replacing the treating physician’s responsibility for individual care.[1]It addresses cervical cancer as a major public-health concern and prioritises active screening to detect precancerous lesions early and reduce invasive disease.[2][3]

• Prevent disease through sexual-health education, vaccination against human papillomavirus (HPV), and organised population-based screening rather than reliance on opportunistic individual testing.[4]
• Increase regular screening participation among eligible women, recognising that HPV vaccination does not replace cervical screening.[4][5][6]
• Standardise diagnosis through cervical cytology, colposcopy, biopsy and histopathology, using Bethesda 2001 terminology for cytology reporting and histological confirmation for invasive cancer.[7][8]
• Assess tumour extent and guide treatment selection through pathological classification, clinical examination and stage-appropriate imaging, particularly pelvic magnetic resonance imaging.[9][10]
• Deliver treatment adapted to disease stage, tumour characteristics, nodal status, general health, fertility wishes, sexuality and pregnancy status, using surgery, radiotherapy, brachytherapy and chemotherapy alone or in combination.[11][12][5][13]
• Support survivorship by addressing treatment effects, late complications, recurrence, pain, fatigue, nutrition, sexual health, psychological wellbeing, relationships and professional circumstances.[14]
• Manage surgical, urological and radiotherapy complications and assess recurrent cancer on a case-by-case basis.[15][16][17]

Implementation

Implementation is based on multidisciplinary expert guidance coordinated nationally and applied across the clinical pathway, from prevention and screening to diagnosis, treatment, surveillance, complication management and supportive care.[1][18]Care is intended to be delivered by specialist multidisciplinary teams, with patient information, agreement and individual clinical judgement integral to management.[13]

• Coordinate development through the Ministry of Health, the National Health Insurance Agency and the Moroccan Society of Medical Sciences, with participation from national learned societies and university and private-sector specialists.[18]
• Convene specialist working groups, inter-group meetings and plenary synthesis sessions, culminating in collective validation of the recommendations.[18]
• Involve gynaecologists, oncologists, pathologists, surgeons, general practitioners, urologists, radiologists and other relevant professionals in developing and delivering care.[19][20][21]
• Provide primary prevention through HPV vaccination against types 16 and 18 for previously uninfected patients, while recognising that vaccination is not therapeutic for established infection or associated lesions.[4]
• Organise secondary prevention through cervical-smear screening from the beginning of sexual activity or age 25, with two annual repeat tests followed by three-yearly testing when results are normal and symptoms are absent.[4]
• Investigate symptoms suggestive of cervical disease through medical advice, gynaecological examination, speculum, vaginal and rectal examination where indicated, and cervical biopsy to confirm suspected invasive cancer and its histological type.[22][8]
• Use conventional or liquid-based cytology for screening, with liquid-based methods potentially reducing uninterpretable samples and allowing HPV typing from the same specimen.[7]Use HPV typing selectively for specified equivocal cytology or discordant colposcopic findings rather than as a first-line test.[8]
• Use colposcopy-directed biopsy for subclinical lesions and biopsy visible lesions; repeat a non-conclusive biopsy because biopsy is required to confirm invasive disease.[8]
• Stage and plan treatment using histopathology, pelvic magnetic resonance imaging and additional examinations according to disease extent.[9][10]Use fluorodeoxyglucose positron emission tomography particularly for nodal assessment in appropriate stage IB2 disease and selected other cases.[9]
• Deliver treatment in an authorised gynaecological-cancer establishment through a team incorporating clinical, diagnostic, nursing, nutritional, psychological and social-work expertise.[13]Discuss complete records across specialties, explain proposed treatment clearly and obtain the patient’s agreement.[13]
• Adapt management of pre-invasive lesions and invasive disease to pathology, stage, visibility of the transformation zone, excision margins, surveillance capacity and fertility considerations.[23][11]
• Coordinate follow-up among the primary doctor, gynaecologist and specialist treatment team, sharing information and providing continuing supportive care through facilities, community services or health networks.[14]
• Schedule general and gynaecological follow-up every four months for two years, every six months for the following three years and annually thereafter, adapting timing to symptoms and clinical history.[12][6]Use imaging, blood tests, biopsy or cytological sampling when clinically indicated rather than routinely.[6][14]
• Monitor complication risks, including urinary obstruction, renal function, lymphoceles and radiotherapy effects.[15][16]Keep severe radiotherapy complications below 2 to 3% in early-stage cancers and 5 to 8% in advanced cancers.[16]
• Recognise that the supplied material does not specify a formal implementation timetable, programme-level reporting system, comprehensive indicator framework, dedicated budget, financing mechanism or institutional accountability structure beyond the expert and multidisciplinary arrangements described.[19][18][15]

Monitoring & Evaluation

Monitoring provisions are principally clinical rather than programme-level. They cover screening intervals, cytology quality and diagnostic reporting, staging, treatment follow-up, detection of recurrence, and safety monitoring for complications; however, the guideline does not establish a national indicator set, reporting schedule, surveillance information system, audit cycle, performance targets, or formal accountability framework.[1][2][7][9][15]

• Use organised, population-based cervical screening rather than relying primarily on opportunistic individual prescriptions, with vaccination presented as complementary to, rather than a replacement for, screening.[4][5]
• Apply screening from the beginning of sexual activity or age 25, repeat testing twice at one-year intervals, and subsequently screen every three years where results remain normal and the patient has no symptoms.[4]
• Adapt surveillance following negative cytology to Moroccan circumstances and clinical judgement, while the cited pathway indicates three-yearly testing after two normal smears.[24]
• Assess cervical cytology quality by recording whether specimens are satisfactory or unsatisfactory for evaluation and documenting the reason for inadequacy; reports may also identify automated processing and human papillomavirus testing.[25][26]
• Standardise cytology reporting through the Bethesda 2001 terminology, including negative findings, atypical squamous cells, low- and high-grade squamous intraepithelial lesions, glandular abnormalities, adenocarcinoma in situ, adenocarcinoma, microorganisms and other specified changes.[7][26]
• Recognise that conventional cytology has variable reported sensitivity and specificity, while liquid-based cytology may reduce difficult-to-read or uninterpretable smears and may allow human papillomavirus molecular typing from the same specimen.[7]
• Interpret evidence on liquid-based cytology cautiously: a cited meta-analysis found greater high-grade lesion detection in cohort comparisons, but studies in which all women underwent colposcopy and histological verification found no significant difference in sensitivity or specificity for high-grade lesions.[7]
• Repeat a non-conclusive biopsy and require biopsy to confirm invasive cancer; use histopathology, imaging and nodal assessment to support tumour classification, staging, treatment planning, prognosis and post-treatment surveillance.[8][9]
• Follow patients after treatment with general and gynaecological examinations every four months for two years, every six months for the next three years, and annually thereafter, with adjustment for symptoms and clinical history.[12][6][14]
• Use imaging, biological tests, cervical smears, biopsy or cytological sampling when clinically indicated rather than routinely, to investigate symptoms, recurrence or treatment effects.[12][6][14]
• Note an inconsistency in smear follow-up provisions: one section describes smears at six and twelve months and then annually after conservative treatment, whereas another post-treatment section specifies no surveillance smear.[5][6]
• Monitor selected pre-invasive lesions through repeat smears, colposcopy, biopsy, endocervical assessment, diagnostic conisation and, where applicable, human papillomavirus testing pathways.[24][23]
• Monitor post-operative complications, including lymphoceles through imaging when asymptomatic, and assess ureteric obstruction by laterality, renal cortical condition, renal function and recovery after urinary diversion.[15]
• Use severe radiotherapy-complication rates as an explicit safety threshold, not exceeding 2 to 3% for early-stage cancers and 5 to 8% for advanced cancers.[16]
• Recognise that national epidemiological information is incomplete because national cervical-cancer data are unavailable; available estimates draw on the Casablanca and Rabat cancer registries and institutional data.[2]
• Assign the treating physician an important role in follow-up and management of disease- or treatment-related complications, while coordinating care with gynaecology and specialist treatment teams and sharing relevant information.[5][14]

Costing & Financing

No explicit costing, budget, financing source, resource-mobilisation plan, funding gap, allocation formula or economic assumption is provided for prevention, vaccination, screening, diagnosis, treatment, follow-up, supportive care or complication management.[19][4][10][15][14]

• Identify substantial service inputs, including organised screening, human papillomavirus vaccination, cytology and histopathology, pelvic magnetic resonance imaging, positron emission tomography, surgery, radiotherapy, brachytherapy, chemotherapy, specialist multidisciplinary care and psychosocial support, but do not attach monetary values or funding arrangements to them.[4][9][10][13][14]
• Note that treatment quantities and timing, including radiotherapy doses and intervals, are described clinically without corresponding monetary costs.[24]
• Leave resource requirements, affordability, cost-effectiveness, financial responsibilities and the means of addressing any funding shortfall unspecified.[18][7][12][5]